SCHEMBL3280663

SCHEMBL3280663

COc1ccc(-c2cc3ncccc3c(Cl)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.71
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
ACP1 P24666 6/20 0.52
MAPT P10636 2/20 0.51
ACACA Q13085 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284282 0.86 SYK (0.60) SYKNPC1RAB9AKDM4ELMNA
SCHEMBL524226 0.84 SYK (0.55) SYKACACA
SCHEMBL3281714 0.83 SYK (0.71) SYKNPC1RAB9AACP1MAPT
SCHEMBL11365024 0.83 SYK (1.00) SYKNPC1RAB9AACP1MAPT
SCHEMBL524455 0.83 SYK (0.53) SYKNPC1RAB9AACP1MAPT
SCHEMBL523788 0.83 SYK (0.50) SYKNPC1RAB9AACP1MAPT
SCHEMBL3287166 0.82 SYK (0.70) SYKNPC1RAB9AACP1MAPT
SCHEMBL590118 0.81 SYK (1.00) SYKNPC1RAB9AACP1MAPT
SCHEMBL523765 0.81 SYK (0.64) SYK
SCHEMBL22201437 0.81 PRKCH (0.56) SYKNPC1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705151-B2 1,6 Naphthridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678911-B2 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-07-02 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE CYWIN CHARLES L 2008-05-15 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-7321041-B2 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-01-22 US disclosed
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-12-11 US disclosed
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed
WO-2003057695-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229090-A1 1,6 Naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK SYK 1/4885NPC1 1817/4885RAB9A 851/4885
US-20080114024-A1 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 SYK 1/4885NPC1 1376/4885RAB9A 692/4885
US-20090171089-A1 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE SYK, IRAK1, IRAK3 SYK 1/4885NPC1 1304/4885RAB9A 759/4885
US-20030158195-A1 1,6 naphthyridines useful as inhibitors of SYK kinase SYK, IRAK1, BTK SYK 1/4885NPC1 1817/4885RAB9A 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.